Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness
Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness in patients undergoing breast cancer surgery during general anesthesia
Zhiming Tan
900 participants
Jan 21, 2010
Interventional
Conditions
Summary
Extensive evidence has proved that basal forebrain cholinergic system play extremely important role in explicit memory.Penehyclidine hydrochloride (PHC; (2-hydroxyl-2-cyclopentyl-2-phenyl-ethoxy) quinuclidine) is a new anticholinergic drug with both antimuscarinic and antinicotinic activity while retaining potent central and peripheral anticholinergic activity.The primary purpose of this study is to verify the effectiveness of PHC reducing the incidence of intraoperative awareness. Modified Brice interview was used to assess awareness in the study.
Eligibility
Inclusion Criteria1
- American Society of Anesthesiologists physical status I–III patients, aged 15–75 years, undergoing breast cancer surgery
Exclusion Criteria1
- psychosis or memory impairment, history of intraoperative awareness or brain injury, history of electroencephalographic abnormality, patients habitually using benzodiazepines, opiates, alcohol, barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampicin etc. and patients who are unable to provide informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients receive 0.01 mg.kg-1 Penehyclidine Hydrochloride intravenously 30min before surgery
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611001229965